NCT06944145View on ClinicalTrials.gov

New Treatment Strategies and Epigenetic Biomarker for Management of BPH

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

June 1, 2029

Study Completion Date

August 31, 2030

Conditions
BPH (Benign Prostatic Hyperplasia)
Interventions
DRUG

raloxifene

Participants in the Finasteride + Raloxifene Combination Therapy Arm will receive both Finasteride and Raloxifene as their intervention.

DRUG

Finasteride

"Participants in the Finasteride Monotherapy arm will receive only Finasteride as their standard-of-care intervention.~Participants in the Finasteride + Raloxifene Combination Therapy arm will receive both Finasteride and Raloxifene as the study intervention."

All Listed Sponsors
lead

Beth Israel Deaconess Medical Center

OTHER